Avatar
Locust73buta

0 Following 0 Followers
1
Nium Pharmaceuticals, Inc., the manufacturer of TAK733. Acknowledgements This work was funded by The Seaver Institute, the Melanoma Research Foundation, the Melanoma Research Alliance, the Louise Belley and Richard Schnarr Fund, the Wesley Coyle Memorial Fund, the Garcia-Corsini Family Fund, the Keiter Family Foundation and the Caltech-UCLA Joint Center for Translational Medicine (all to A.R.). Au
1
Ww.molecular-cancer.com/content/11/1/Page 8 ofIllumina Beadchip Human Exon 510 S-Duo (Illumina Inc., San Diego, CA).Additional filesAdditional file 1: Figure S1 TAK733 MTS-based colorimetric cell proliferation assay curves in melanoma cell lines of cutaneous origin according to their BRAF (A) or NRAS (B) mutational status, WT (C) and of uveal origin (D). Modulation of the melanoma cell line viabil
1
Les, CA, USA. 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. 6Division of Hematology-Oncology, 11?34 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.Western blottingWestern blotting was performed as previously described [31]. Primary antibodies included pAkt (Ser473), pAkt (Thr308), Akt, pS6K (Thr389), S6K, pS6 (Ser235/236), S6, pMEK (Ser217/22
1
Les, CA, USA. 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. 6Division of Hematology-Oncology, 11?34 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.Western blottingWestern blotting was performed as previously described [31]. Primary antibodies included pAkt (Ser473), pAkt (Thr308), Akt, pS6K (Thr389), S6K, pS6 (Ser235/236), S6, pMEK (Ser217/22
1
Les, CA, USA. 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. 6Division of Hematology-Oncology, 11?34 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.Western blottingWestern blotting was performed as previously described [31]. Primary antibodies included pAkt (Ser473), pAkt (Thr308), Akt, pS6K (Thr389), S6K, pS6 (Ser235/236), S6, pMEK (Ser217/22
1
Les, CA, USA. 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. 6Division of Hematology-Oncology, 11?34 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.Western blottingWestern blotting was performed as previously described [31]. Primary antibodies included pAkt (Ser473), pAkt (Thr308), Akt, pS6K (Thr389), S6K, pS6 (Ser235/236), S6, pMEK (Ser217/22
1
Les, CA, USA. 5 Millennium Pharmaceuticals, Inc., Cambridge, MA, USA. 6Division of Hematology-Oncology, 11?34 Factor Building, UCLA Medical Center, 10833 Le Conte Avenue, Los Angeles, CA 90095-1782, USA.Western blottingWestern blotting was performed as previously described [31]. Primary antibodies included pAkt (Ser473), pAkt (Thr308), Akt, pS6K (Thr389), S6K, pS6 (Ser235/236), S6, pMEK (Ser217/22
1
R.com/content/11/1/Page 9 of7.8.9.10.11.12.13.14.15.16.17.18.19.20.21.22.23.24.25.Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358?62. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al: Clinical efficacy of a RAF inhibitor ne